TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3117554

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (2.5 mg in 49% and 5.0 mg in 51%)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin
Number of subjects: 126
Study: 29929682

Group type: EXPERIMENTAL
Intervention: Computer-facilitated 5A's intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 221
Study: 27113188

Group type: EXPERIMENTAL
Intervention: 3D reconstruction of lung cancer using Mimics software on a personal computer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional surgical scheme
Number of subjects: 24
Study: 25111351

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 22768661

Group type: EXPERIMENTAL
Intervention: Alfacalcidol with 400 mg of elemental calcium daily for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Menatetrenone with 400 mg of elemental calcium daily for 12 months
Number of subjects: 20
Study: 20547822

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided TAP blocks (2 x 20 mL 0.5% ropivacaine)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Multimodal IV analgesia with placebo (0.9% saline)
Number of subjects: 65
Study: 17984215

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Pharmacological treatment alone
Number of subjects: 813
Study: 15973773

Group type: EXPERIMENTAL
Intervention: Tripterysium glucosides for three months with prednisone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) by intermission intravenous pulse with prednisone
Number of subjects: 80
Study: 11841992

Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10028936

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 30
Study: 10829886

Group type: EXPERIMENTAL
Intervention: Gentamicin for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 40
Study: 1439313

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (followed 2‐162 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thyroidectomy (followed 2‐158 months)
Number of subjects: 20
Study: 3026005

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin plus gentamicin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clindamycin alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 41
Study: 29757845

Group type: EXPERIMENTAL
Intervention: Acute care nurse practitioner (ACNP) presence during daily ICU multidisciplinary rounds
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no ACNP presence during rounds)
Number of subjects: 81
Study: 27487253

Group type: EXPERIMENTAL
Intervention: TEG‐adjusted enoxaparin dosing (35 mg twice daily)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard dosing (30 mg twice daily)
Number of subjects: 185
Study: 25527750

Group type: EXPERIMENTAL
Intervention: Polydextrose (21 g/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (SCF; 21 g/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fiber supplementation (polydextrose and SCF combined)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NFC (no supplemental fiber)
Number of subjects: 21
Study: 23717826

Group type: EXPERIMENTAL
Intervention: Pain vigilance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pain catastrophizing and fear of pain
Number of subjects: 40
Study: 21204914

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 18057215

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment in patients with CKD
Number of subjects: 5154

Group type: COMPARATOR
Intervention: Placebo treatment in patients with CKD
Number of subjects: 5154

Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 5154
Study: 16688995

Group type: EXPERIMENTAL
Intervention: Shexiang Injection (SI) plus conventional therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 42
Study: 12702115

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (proximal furcation defects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (proximal furcation defects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (facial/lingual defects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (facial/lingual defects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (proximal defects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (proximal defects)
Number of subjects: 31
Study: 10750647

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 every 4 weeks) + Tamoxifen (30 mg bid)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tamoxifen (30 mg bid)
Number of subjects: 32
Study: 7475043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 20
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 50
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 100
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 150
Number of subjects: 87
Study: 2125857

Group type: EXPERIMENTAL
Intervention: Ritanserin (30 mg daily p.o.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Orphenadrine (150 mg daily p.o.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7032224

Group type: EXPERIMENTAL
Intervention: Long-acting neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31083802

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in cirrhotic patients
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in non-cirrhotic patients
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in patients without end-of-treatment response (EoTR)
Number of subjects: 334
Study: 28771524

Group type: EXPERIMENTAL
Intervention: Brief case management
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study: 26154029

Group type: EXPERIMENTAL
Intervention: Formula with 0.2 g/L 2'FL
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Formula with 1.0 g/L 2'FL
Number of subjects: 254

Group type: COMPARATOR
Intervention: Formula with 64.3 kcal/dL (control group)
Number of subjects: 254

Group type: COMPARATOR
Intervention: HM-fed infants (control group)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: All formulas (including those with 2'FL)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 2'FL supplementation
Number of subjects: 254
Study: 24191398

Group type: EXPERIMENTAL
Intervention: PIR
Number of subjects: 320

Group type: COMPARATOR
Intervention: PIR-taping
Number of subjects: 320
Study: 21638277

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 280
Study: 20001837

Group type: EXPERIMENTAL
Intervention: Standard sensory integration therapy with Thai Traditional Massage (TTM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard sensory integration therapy (SI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard sensory integration therapy with TTM
Number of subjects: 60
Study: 16282579

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study: 15478167

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 7
Study: 10997428

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg inhalation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Non-dependent zones of the lung
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bronchodilator response assessment
Number of subjects: 22
Study: 9062615

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group with antegrade cardioplegia
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group with retrograde cardioplegia
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: RCA-ante group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: RCA-retro group
Number of subjects: 58

Group type: COMPARATOR
Intervention: C-ante group
Number of subjects: 58

Group type: COMPARATOR
Intervention: C-retro group
Number of subjects: 58
Study: 8202769

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 3297810

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (p)
Number of subjects: 16
Study: 29273206

Group type: EXPERIMENTAL
Intervention: Top group of CVH score (≥10 points)
Number of subjects: 200
Study: 26456812

Group type: EXPERIMENTAL
Intervention: Chemotherapy (primary treatment for ovarian cancer)
Number of subjects: 231
Study: 23456327

Group type: EXPERIMENTAL
Intervention: Exposure to spoken words with vowel harmony in the voice of a single talker.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Familiar talker accent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfamiliar talker accent
Number of subjects: 0
Study: 20624273

Group type: EXPERIMENTAL
Intervention: Optilene Mesh Elastic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrapro Mesh
Number of subjects: 80
Study: 18445839

Group type: EXPERIMENTAL
Intervention: Pharmacokinetically guided FU dose adjustment (arm B)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional dosing of fluorouracil (arm A)
Number of subjects: 208
Study: 16766630

Group type: EXPERIMENTAL
Intervention: Molecular genetics approaches
Number of subjects: 0
Study: 12727395

Group type: EXPERIMENTAL
Intervention: Educational intervention to promote exclusive breastfeeding
Number of subjects: 1115
Study: 11032209

Group type: EXPERIMENTAL
Intervention: Fluid administered during the first 48 hours (mean=5824 mL)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: BUN level (mean=34)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Age (mean=59 years)
Number of subjects: 125
Study: 8773160

Group type: EXPERIMENTAL
Intervention: Aspirin 975 mg qid for 4 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg qid for 4 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glyburide 5 mg plus GTT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline oral glucose tolerance test (GTT)
Number of subjects: 16
Study: 1553404

Group type: EXPERIMENTAL
Intervention: Temperature biofeedback-assisted relaxation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Attention control, 'stress education'
Number of subjects: 19
Study: 3883729

Group type: EXPERIMENTAL
Intervention: Captopril (37.5 to 75 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol (60 to 120 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study: 30843623

Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 30165520

Group type: EXPERIMENTAL
Intervention: Unchanged LT4 dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Higher LT4 dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lower LT4 dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Perceived higher LT4 doses
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Adjusting LT4 doses
Number of subjects: 138
Study: 27424010

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2.4 g/day for 8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (paraffin)
Number of subjects: 72
Study: 24861034

Group type: EXPERIMENTAL
Intervention: Pronase premedication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) endoscopy with pronase premedication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pronase premedication)
Number of subjects: 0
Study: 22397629

Group type: EXPERIMENTAL
Intervention: PCV7 vaccination
Number of subjects: 4405
Study: 19149498

Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine-laden therapeutic contact lenses
Number of subjects: 0
Study: 17461355

Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy for oropharyngeal dysphagia (specific therapeutic programs not sufficiently described)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swallowing training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speech-language intervention
Number of subjects: 0
Study: 15304592

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12527501

Group type: EXPERIMENTAL
Intervention: Total edentulous
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Edentulous in one jaw
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Remaining sound teeth, decayed teeth, radices relictae
Number of subjects: 274
Study: 9583547

Group type: EXPERIMENTAL
Intervention: Paravertebral administration of bupivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Interpleural administration of bupivacaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (Paravertebral and Interpleural)
Number of subjects: 12
Study: 8608752

Group type: EXPERIMENTAL
Intervention: 24-bit color images
Number of subjects: 11

Group type: COMPARATOR
Intervention: 16-bit color images
Number of subjects: 11

Group type: COMPARATOR
Intervention: 8-bit color images
Number of subjects: 11
Study: 2534170

Group type: EXPERIMENTAL
Intervention: 1 g of cefotaxime during resection and another 1 g dose when the bladder catheter was removed
Number of subjects: 50

Group type: COMPARATOR
Intervention: no additional cefotaxime dose when the bladder catheter was removed
Number of subjects: 50
Study: 5801347

Group type: EXPERIMENTAL
Intervention: Elema‐Schonander electrodes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dracard electrodes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Smith and Nephew electrodes
Number of subjects: 8
Study: 31634980

Group type: EXPERIMENTAL
Intervention: QSAR model for predicting acute toxicity (LC50) of pesticides
Number of subjects: 0
Study: 28432007

Group type: EXPERIMENTAL
Intervention: 200 ml orange-flavored beverage (0 kcal vs. 200 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 ml water (0 kcal) vs. 200 ml strawberry milkshake (200 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overweight/obese children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese/overweight children
Number of subjects: 0
Study: 25544403

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 36
Study: 23895363

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control Intervention (CTL)
Number of subjects: 180
Study: 22129569

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Immediate-release (IR) cilostazol 100 mg × 2 tablets, BID
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily (fed state)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multiple doses of SR and IR formulations for 8 consecutive days
Number of subjects: 92
Study: 19189982

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg h(‐1) at 0.5% concentration with sufentanil 2.6 microg h(‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg h(‐1) at 0.25% concentration with sufentanil 2.6 microg h(‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg h(‐1) at 0.15% concentration with sufentanil 2.6 microg h(‐1)
Number of subjects: 150
Study: 17491176

Group type: EXPERIMENTAL
Intervention: Web‐based tailored behavioral smoking cessation materials
Number of subjects: 3971

Group type: COMPARATOR
Intervention: Web‐based nontailored materials
Number of subjects: 3971
Study: 15648962

Group type: EXPERIMENTAL
Intervention: Peroral norfloxacin (n = 25)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin and sulbactam (n = 21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (cirrhosis patients hospitalized for other reasons)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Throat swab culture
Number of subjects: 46
Study: 11703222

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 9164913

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pravastatin and nicotinic acid
Number of subjects: 0
Study: 8435884

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g four times per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (4 g four times per day)
Number of subjects: 15
Study: 3316058

Group type: EXPERIMENTAL
Intervention: Imidazole salicylate (750 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg t.i.d.)
Number of subjects: 0
Study: 28827188

Group type: EXPERIMENTAL
Intervention: Capecitabine-containing treatment (ATX)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (AT)
Number of subjects: 188
Study: 27256087

Group type: EXPERIMENTAL
Intervention: Simulation-based education (SBE) training for the Safe Recovery program
Number of subjects: 0
Study: 24615657

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anacetrapib 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study: 22430688

Group type: EXPERIMENTAL
Intervention: Oral-B mouthrinse (OB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse (LN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rembrandt Plus mouthrinse (RM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Excite adhesive system (EX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clearfil SE Bond adhesive system (CSE)
Number of subjects: 60
Study: 21176626

Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography ≤ 24 hours after randomization)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography ≥ 36 hours after randomization)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 815
Study: 18480691

Group type: EXPERIMENTAL
Intervention: Agomelatine (50 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Venlafaxine XR (titrated to 150 mg/d)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 276
Study: 16043216

Group type: EXPERIMENTAL
Intervention: Mailed reminder (minimum group)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Mailed thank you card, newsletters, and reminder (maximum group)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: No mailings (control)
Number of subjects: 1558
Study: 12154114

Group type: EXPERIMENTAL
Intervention: BQ-123 (ET(A) receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydralazine (control dilator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 10404920

Group type: EXPERIMENTAL
Intervention: Intervention combining increased daytime physical activity (14 weeks) plus a nighttime program (5 nights) to decrease noise and sleep-disruptive nursing care practices
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nighttime program alone (control group)
Number of subjects: 29
Study: 7587797

Group type: EXPERIMENTAL
Intervention: fedotozine 30 mg three times a day
Number of subjects: 238

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 238
Study: 2383162

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g/d intravenously for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (after initial placebo treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 60
Study: 6454249

Group type: EXPERIMENTAL
Intervention: Dicloxacillin administration for 6 days per- and postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Improved hygienic routines
Number of subjects: 60